Tenderwize
Retour à la recherche

Non-exclusive Drug Discount Agreement for Aripiprazole (Parenteral)

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Mar 31, 2027 · 215 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Aripiprazol für die parenterale Applikation (ATC-Code nach WHO: N05AX12)

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

20 / 100

Facteurs de risque

No guaranteed volume; actual sales depend on prescription and pharmacy behavior, leading to unpredictable revenue.

Early termination risk: buyer may cancel the Open House if exclusive agreements are made (typically 8-12 months after p...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Mar 2027
  • Conclusion of non-exclusive discount agreements for Aripiprazole parenteral products
  • Supply of pharmaceutical products to AOK PLUS for patients in Saxony and Thuringia
Afficher le résumé complet

This Open House model tender by AOK PLUS seeks non-exclusive discount agreements under §130a Abs. 8 SGB V for the active substance Aripiprazole for parenteral administration (ATC N05AX12). The framework agreement is open to all eligible pharmaceutical companies meeting participation requirements. No exclusivity, no minimum purchase quantities, and no estimated value are provided. The contract runs until 31 March 2027. Submissions are accepted periodically, with the first deadline on 5 March 2025. The procedure is not subject to public procurement law; the notice is published for transparency. All communication and document access are via the DTVP portal, with strict confidentiality required.

Risques

No guaranteed volume; actual sales depend on prescription and pharmacy behavior, leading to unpredictable revenue.

Early termination risk: buyer may cancel the Open House if exclusive agreements are made (typically 8-12 months after p...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical company as defined by §4 Abs. 18 AMG for the offered products

Eligibility

  • Submit self-declaration on exclusion grounds (GWB §§123,124)

Administrative

  • Submit self-declaration regarding EU Russia sanctions (Art. 5k of Regulation 833/2014)

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No explicit award criteria specified in the notice. Participation is open to all fulfilling conditions.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Non-exclusive Drug Discount Agreement for Aripiprazole (Parenteral)

Framework agreement for non-exclusive discount agreements on Aripiprazole parenteral formulations. Open House model; no exclusivity, no guaranteed volumes. Contract ends 31 March 2027.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Mar 2025 - Mar 2027

Catégorie

Pharmaceutical products

Critères d'attribution

No explicit award criteria specified in the notice. Participation is open to all fulfilling conditions.

Date limite

Deadline Mar 31, 2027

Détails de la procédure

Date de publication
22 Jan 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
48010-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30